Answers are grounded in this paper and cite their sources.
Aim: To present data from three studies of a Post-Authorization Safety Surveillance (PASS) program for the subset of patients receiving Octagam® 5% or 10% for chronic inflammatory demyelinating polyneuropathy (CIDP). Methods: Data on patients with CIDP treated with Octagam were analyzed to assess its safety and tolerability. Results: Of 2314 patients included in the studies, 58 patients (mean age: 64.6 years) received Octagam for CIDP, mean dose of which was 0.8 g/kg bodyweight/course. 81% of observations for clinical appearance since last observation were assessed as stable and 16.6% showed an improved clinical appearance with treatment. Adverse drug reactions were rare (<0.7% of infusions). Conclusion: Octagam was effective and well-tolerated in patients with CIDP.
No takes yet. Share an insight, caveat, or question.
Stefan Wietek (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: